As far as we have come in terms of better controlling hypertension, overall treatment efficacy will undoubtedly continue to improve with the advent of novel classes of agents and application of device approaches for treating hypertension. Although no new classes of antihypertensive agents seem likely to be immediately available to clinicians, progress continues with a variety of new classes, including early clinical assessments of aldosterone synthase inhibitors, neutral endopeptidase inhibitors and non-steroid mineralocorticoidreceptor antagonists. As development of these and other novel classes of agents progress, even better blood pressure control and, perhaps, potentially unique benefits in terms of preventing hypertension, improving vascular function and better protecting end-organs does not seem far fetched.
Particularly exciting is the early promise of suppressing sympathetic activity with procedures that stimulate carotid sinus baroreceptors or that denervate the kidneys. The magnitude of reduction in clinic blood pressure reported in the first trials of these devices is extraordinary. Confirmation with longer-term, randomized assessments of this degree of antihypertensive benefit will highlight the probably under-appreciated role that sympathetic activation has in causing resistant hypertension. The recent findings from these device trials also indicate that we, as clinicians, do not have an effective method to accurately gauge the role of sympathetic overactivation in causing treatment resistance, nor do we have effective pharmacological agents to suppress sympathetic activity, at least with doses that are well tolerated. Such diagnostic and therapeutic deficiencies are obviously areas ripe for continued scientific research.
The new leadership of the JHH will strive to maintain the journal's position as an important venue for dissemination of cutting-edge clinical research in hypertension and vascular disease. The JHH has a strong track record of publishing highquality research from the entire spectrum of hypertension, including pregnancy-related hypertension, children and adolescent hypertension, adult hypertension, and hypertension and vascular disease, in older and even very old cohorts. We look forward to working with investigators to continue publishing original articles with such a broad-based approach. We will also continue to rely on experts worldwide to provide short commentaries and in-depth reviews of important topics in hypertension. It is daunting to imagine building upon the precedent established by the long service of Professor Lip, but given the many, as yet, unmet clinical needs related to preventing, diagnosing and treating hypertension, the importance of meaningful clinical research addressing these needs remains paramount.
